CTOs on the Move

Akcea Therapeutics

www.akceatx.com

 
Akcea Therapeutics is a development and commercialization company focused on helping patients with serious diseases. Our priority is to drive clinical program execution, understand patient and physician needs, prepare the market, create market access, and commercialize our products on a global basis. We are driven by knowing that patients depend on us. An affiliate of Ionis Pharmaceuticals and based in Kendall Square, Cambridge, Massachusetts, Akcea was founded with a robust portfolio of development-stage drugs covering multiple targets and disease states using advanced antisense therapeutics. Akcea is derived from the Greek word for value and worth. Something that has akcea (αξία) ...
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.akceatx.com
  • 22 Boston Wharf Road
    Boston, MA USA 02210
  • Phone: 617.207.0202

Executives

Name Title Contact Details

Similar Companies

Afaxys

Afaxys mission is to deliver products and services to public health providers affordably, reliably and with an unwavering focus on customer service.

Allied Research International

Allied Research International is a Mississauga, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

ARYx Therapeutics

ARYx Therapeutics, Inc. is a Fremont, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Asembia

Asembia constantly connects and strengthens the pharmaceutical industry to improve the experiences of patients everywhere.

SAB Biotherapeutics

SAB Biotherapeutics, Inc. (SAB) is a clinical-stage, biopharmaceutical company advancing a new class of immunotherapies leveraging fully human polyclonal antibodies. SAB has applied advanced genetic engineering and antibody science to develop transchromosomic (Tc) Bovine™ herds that produce fully-human antibodies targeted at specific diseases, including infectious diseases such as COVID-19 and influenza, immune system disorders including type 1 diabetes and organ transplantation, and cancer. SAB`s versatile DiversitAb™ platform is appliable to a wide range of serious unmet needs in human diseases. It produces natural, specifically targeted, high-potency, human polyclonal immunotherapies. SAB is currently advancing multiple clinical programs and has a number of collaborations with the US government and global pharmaceutical companies.